HOUSE_OVERSIGHT_026362.jpg
1.27 MB
Extraction Summary
3
People
8
Organizations
1
Locations
2
Events
1
Relationships
3
Quotes
Document Information
Type:
Email
File Size:
1.27 MB
Summary
This document is an email from Jeffrey Epstein to Sultan Bin Sulayem on July 24, 2015, discussing a new, expensive cholesterol-lowering drug called Praluent. Epstein's email is a reply to an inquiry from Sulayem, who had forwarded a Forbes article announcing the FDA's approval of the drug, which is administered as a shot.
People (3)
| Name | Role | Context |
|---|---|---|
| jeffrey E. | Sender |
Sender of the email from jeevacation@gmail.com, replying to Sultan Bin Sulayem about a new cholesterol drug.
|
| Sultan Bin Sulayem | Recipient / Original Sender |
Recipient of Jeffrey E.'s email and the sender of the original email inquiry about the cholesterol drug.
|
| Matthew Herper | Author / Journalist |
Author of the forwarded Forbes article titled 'The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot'.
|
Organizations (8)
| Name | Type | Context |
|---|---|---|
| Forbes |
Publisher of the article written by Matthew Herper.
|
|
| Food and Drug Administration (FDA) |
The U.S. government agency that approved the drug Praluent.
|
|
| Regeneron Pharmaceuticals |
The biotechnology company that invented the drug Praluent.
|
|
| Wall Street |
Mentioned in the article in the context of analysts' expectations for the cost of Praluent.
|
|
| Google Plus |
Social media platform mentioned in the author's bio.
|
|
|
Social media platform mentioned in the author's bio.
|
||
|
Social media platform mentioned in the author's bio.
|
||
| HOUSE_OVERSIGHT |
Likely refers to the House Oversight Committee, the source of the document as indicated by the footer.
|
Timeline (2 events)
2015-07-24
The FDA approved Praluent, a new cholesterol-lowering injectable drug developed by Regeneron Pharmaceuticals.
United States
2015-07-24
Email exchange between Jeffrey E. and Sultan Bin Sulayem regarding the newly approved cholesterol drug, Praluent.
Locations (1)
| Location | Context |
|---|---|
|
Location of Regeneron Pharmaceuticals, the company that invented Praluent.
|
Relationships (1)
The document is an email chain between Jeffrey E. and Sultan Bin Sulayem on July 24, 2015.
Key Quotes (3)
"yes, it requires a shot, its not a pill and so far no long term effects known"Source
HOUSE_OVERSIGHT_026362.jpg
Quote #1
"Have you heard of this colestrol"Source
HOUSE_OVERSIGHT_026362.jpg
Quote #2
"The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol..."Source
HOUSE_OVERSIGHT_026362.jpg
Quote #3
Full Extracted Text
Complete text extracted from the document (1,533 characters)
From:
jeffrey E. [jeevacation@gmail.com]
Sent:
7/24/2015 8:47:39 PM
To:
Sultan Bin Sulayem
Subject:
Re: FDA Approved a Potent and Pricey Cholesterol lowering drug today
jeffrey E. [jeevacation@gmail.com]
Sent:
7/24/2015 8:47:39 PM
To:
Sultan Bin Sulayem
Subject:
Re: FDA Approved a Potent and Pricey Cholesterol lowering drug today
yes, it requires a shot, its not a pill and so far no long term effects known
On Fri, Jul 24, 2015 at 4:37 PM, Sultan Bin Sulayem wrote:
Have you heard of this colestrol
Have you heard of this colestrol
Jul 24, 2015 @ 3:23 PM 1,169 views
The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot
Matthew Herper,
Forbes Staff
I cover science and medicine, and believe this is biology's century.
Forbes Staff
I cover science and medicine, and believe this is biology's century.
•
Follow on Forbes
(1970)
Follow on Forbes
(1970)
•
•
•
•
•
•
Full Bio
•
Recent Posts
•
Popular Posts
I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page.
•
•
•
•
•
Full Bio
•
Recent Posts
•
Popular Posts
I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page.
Loading...
Loading...
The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins.
It might be a big step in the battle against heart disease - and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost
Loading...
The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins.
It might be a big step in the battle against heart disease - and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost
HOUSE_OVERSIGHT_026362
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document